PeptidePrices safety rating
4/10 · Not FDA-approved
IGF-DES Prices
1 vendor · 0 with an issuer-verified COA · lowest 10mg from $175.47 · checked
Where to buy IGF-DES: 1 vendor compared
| Vendor | Price | Actions |
|---|---|---|
| $175.47 | Buy IGF-DES from Qureshi Labs |
Tracked every day
IGF-DES listing prices, tracked daily
The five cheapest in-stock package prices for IGF-DES on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$49.99
- 2nd cheapest$64.99
- 3rd cheapest$64.99
- 4th cheapest$64.99
Vendors most often in the cheapest five
- Qureshi Labs22 days$64.99+30.0%
Current market data
IGF-DES Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for IGF-DES is $175.47 from Qureshi Labs. The median across vendors is $175.47.
- Lowest 10mg cost
- $175.47Qureshi Labs
- Median 10mg cost
- $175.47One normalized offer per vendor
- Lowest package total
- $44.99Qureshi Labs · package size may differ
- Public COA coverage
- 100%1 of 1 vendors
What the market shows
PeptidePrices found 2 in-stock listings from 1 vendor, checked through Oct 9, 2026. The lowest 10mg cost is 0% below the vendor median of $175.47; 0 vendors (0%) fall below that median. 1 of 1 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is IGF-DES? Research, safety, and status
IGF-DES at a glance
Mechanism
Truncated IGF-1 lacking the first 3 amino acids; does NOT bind IGF binding proteins (IGFBPs), results in 10x greater potency at the receptor vs. standard IGF-1 LR3.
Research areas
Localized muscle hypertrophy (site injection); muscle repair; highly anabolic, more potent per mcg than IGF-1 LR3; bodybuilding and athletic performance.
Regulatory / research status
Research / preclinical only
Half-life
~20-30 minutes (very short, no IGFBP binding). Must be used immediately post-workout for anabolic window.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Hypoglycemia risk, localized muscle swelling, potential for disproportionate site growth, insulin resistance, water retention. Similar risk profile to IGF-1 LR3.
More potent than IGF-1; hypoglycemia proven; tumor promotion concern; mechanistic risk basis Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Des(1-3)IGF-I lacks the N-terminal Gly-Pro-Glu tripeptide and has been isolated from bovine colostrum, human brain tissue, and porcine uterus as a natural post-translational processing product; it demonstrates approximately 10-fold greater cellular potency than full-length IGF-I primarily because it binds negligibly to IGF-binding proteins (IGFBPs), leaving more free peptide available at the receptor.
- A 1989 Biochemical Journal study established the core mechanism: IGFBP preparations that potently inhibited IGF-1 and IGF-2 bioactivity had no inhibitory effect on des-(1-3)-IGF-I, directly demonstrating that biological potency inversely correlates with IGFBP binding affinity.
- Pharmacokinetic studies in rats showed des(1-3)IGF-I clears plasma roughly 3-4× faster than native IGF-I, accumulates preferentially in peripheral tissues including brain and adrenals, and produces greater anabolic effects locally despite its shorter systemic half-life.
- Recombinant fusion protein studies confirmed that the N-terminal tripeptide is the primary structural determinant of IGFBP binding; analogues with that region removed show superior potency in IGFBP-secreting cell lines while retaining equivalent receptor-binding affinity.
Selected references
- Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I · Int J Biochem Cell Biol, 1996
- Insulin-like growth factor binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1 · Biochemical Journal, 1989
- Plasma clearance and tissue distribution of labelled IGF-I, IGF-II and des(1-3)IGF-I in rats · J Endocrinol, 1991
- Novel recombinant fusion protein analogues of IGF-I indicate the relative importance of IGFBP and receptor binding for enhanced biological potency · J Mol Endocrinol, 1992
- Granulosa cell-derived IGFBP are inhibitory to IGF-I: evidence from a truncated IGF-I analogue · J Clin Invest, 1992
- Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts · J Biol Chem, 1996
Related pages